First-line treatment with bevacizumab and paclitaxel prolongs progression-free survival in metastatic breast cancer

Clinical Breast Cancer

Volumn 6, Issue 2, 2005, Pages 105-107

  Tyagi, Preeta ^a   Tripathy, Debu ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; PACLITAXEL;

ADULT; ARTICLE; BLEEDING; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG MECHANISM; FATIGUE; FEMALE; HEART DISEASE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; METASTASIS; NEUROPATHY; NEUTROPENIA; PHASE 3 CLINICAL TRIAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RECURRENT CANCER; THROMBOEMBOLISM;

EID: 22144442421     PISSN: 15268209     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1526-8209(11)70706-6     Document Type: Article

References (17)

1. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30:39-50.
2. McMahon G. VEGF receptor signaling in tumor angiogenesis. Oncologist 2000; 5(suppl 1):3-10.
3. Ferrara N. Role of vascular endothelial growth factor in physiologic and pathologic angiogenesis: therapeutic implications. Semin Oncol 2002; 29(Suppl 16):10-14.
4. Ferrara N, Davis-Smyth T. The biology of vascular endothelial growth factor. Endocr Rev 1997; 18:4-25.
5. Takahashi Y, Kitadai Y, Bucana CD, et al. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer. Cancer Res 1995; 55:3964-3968.
6. Takahashi Y, Tucker SL, Kitadai Y, et al. Vessel counts and expression of vascular endothelial growth factor as prognostic factors in node-negative colon cancer. Arch Surg 1997; 132:541-546.
7. Dy GK, Adjei AA. Novel targets for lung cancer therapy: part II. J Clin Oncol 2002; 20:3016-3028.
8. Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989; 246:1306-1309.
9. Nor JE, Christensen J, Mooney DJ, et al. Vascular endothelial growth factor (VEGF)-mediated angiogenesis is associated with enhanced endothelial cell survival and induction of Bcl-2 expression. Am J Pathol 1999; 154:375-384.
10. Fernando NH, Hurwitz HI. Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer. Semin Oncol 2003; 30:39-50.
11. Kim KJ, Li B, Houck K, et al. The vascular endothelial growth factor proteins: identification of biologically relevant regions by neutralizing monoclonal antibodies. Growth Factors 1992; 7:53-64.
12. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 1993; 362:841-844.
13. Borgstrom P, Gold DP, Hillan KJ, Ferrara N. Importance of VEGF for breast cancer angiogenesis in vivo: implications from intravital microscopy of combination treatments with an anti-VEGF neutralizing monoclonal antibody and doxorubicin. Anticancer Res 1999; 19:4203-4214.
14. FDA Approves First Angiogenesis Inhibitor to Treat Colorectal Cancer [press release]. February 26, 2004. Rockville, MD: FDA, 2004. Available at: http://www.fda.gov/bbs/topics/news/2004/new01027.html. Accessed June 18, 2004.
15. Sandler AB, Gray R, Brahmer J, et al. Randomized phase II/III Trial of paclitaxel (P) plus carboplatin (C) with or without bevacizumab (NSC # 704865) in patients with advanced non-squamous non-small cell lung cancer (NSCLC): an Eastern Cooperative Oncology Group (ECOG) Trial - E4599. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Abstract LBA4.
16. Miller KD, Chap LI, Holmes FA, et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J Clin Oncol 2005; 23:792-799.
17. Miller KD, Wang M, Gralow J, et al. E2100: a randomized phase III trial of paclitaxel versus paclitaxel plus bevacizumab as first-line therapy for locally recurrent or metastatic breast cancer. Presented at the 41st Annual Meeting of the American Society of Clinical Oncology; May 13-17, 2005; Orlando, FL. Available at: http://www.asco.org/ac/1,1003,_12-002511-00_18-0034-00_19- 005814-00_21-00,00.asp. Accessed June 24, 2005.